• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Elocom cream 0.1%, 30g — Made in Belgium — Free Delivery

    Elocom cream 0.1%, 30g — Made in Belgium — Free Delivery


    Brand: Schering-Plough Labo N.V.
    Product Code: Elocom 0.01%
    Availability: In Stock
    $31.25
    Add to Cart

    Pharmacological properties

    Mometasone furoate is a synthetic corticosteroids for topical use. has anti-inflammatory, antipruritic and antiexudative effects.
    Pharmacokinetics. The results of the study showed that systemic absorption after topical application of mometasone furoate 0.1% is minimal; about 0.4% of the dose is excreted from the body within 72 hours after application. It was practically impossible to establish the nature of the metabolites due to the small amount in the blood plasma and excrement.

    Indications

    Inflammation and itching in dermatoses sensitive to corticosteroid therapy, including psoriasis (except for common plaque psoriasis) and atopic dermatitis, in adults and children over the age of 2 years.
    Elokom lotion is also used to treat dermatoses on the surface of the scalp.

    Application

    Ointment or cream is applied in a thin layer to the affected skin once a day. the duration of treatment depends on the severity, course of the disease and is determined individually.
    The use of topical corticosteroids in children and on the face should be limited to the minimum amount compared to effective therapeutic regimens, while the duration of treatment should not exceed 5 days.
    A few drops of lotion are applied to the affected skin once a day and rubbed gently and thoroughly until completely absorbed.

    Contraindications

    Rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal and genital itching, rash due to wearing diapers, bacterial (eg impetigo, pyoderma), viral (eg herpes zoster, herpes zoster and chickenpox, simple warts, genital warts, contagiosus), contagiosum parasitic and fungal (for example, dermatophytosis or caused by candida) infections, tuberculosis, syphilis or post-vaccination reactions. the preparation should not be applied to wounds or ulcerated skin. the preparation is contraindicated in patients with hypersensitivity to any of the components of the preparation or other corticosteroids.

    Side effects

    Below are the adverse reactions reported in connection with the use of the preparation, by organ system and frequency: very often (≥1 / 10); often (≥1 / 100, 1/10); infrequently (≥1 / 1000, 1/100); rarely (≥1 / 10,000, 1/1,000); very rare (1/10 000); unknown (cannot be estimated from the available data).
    Infections and invasions: very rarely - folliculitis; unknown - infections, boils.
    From the side of the nervous system: very rarely - a burning sensation; unknown - paresthesia.
    On the part of the skin and subcutaneous tissue: very rarely - itching; unknown - contact dermatitis, skin hypopigmentation, hypertrichosis, atrophic stripes on the skin, acne-like dermatitis, skin atrophy.
    General disorders and reactions at the site of application: unknown - pain at the site of application, reactions at the site of application.
    Propylene glycol, which is part of the preparation, can cause skin irritation. Local adverse reactions, which have rarely been reported in connection with the use of topical dermatological corticosteroids, include: dryness and irritation of the skin, dermatitis, perioral dermatitis, skin maceration, striae, prickly heat and telangiectasias, papular, pustular eruptions, and tingling sensations.

    Special instructions

    If irritation or increased sensitivity is noted during the use of the preparation, treatment should be discontinued and appropriate therapy prescribed.
    If a concomitant skin infection develops, an appropriate antifungal or antibacterial agent should be used. If a positive effect cannot be achieved for a short time, the preparation should be discontinued until the signs of infection are eliminated.
    Systemic absorption with local application of various GCS can cause a reversible inhibition of the function of the hypothalamic-pituitary-adrenal system with possible GCS insufficiency after discontinuation of treatment. Some patients may develop manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
    Patients using a topical steroid on large areas of the skin or using occlusive dressings should be periodically checked for suppression of the hypothalamic-pituitary-adrenal system. This can be done by performing an ACTH stimulation test, measuring morning plasma cortisol levels and other media other than urine.
    Any side effects that occur with the use of systemic corticosteroids, including inhibition of the function of the adrenal cortex, can also be observed with local administration of corticosteroids, especially in infants and children.
    In children, as well as on the face area, occlusive dressings are not used. Avoid getting the preparation on the mucous membrane.
    Topical steroids can be dangerous in psoriasis for many reasons, including relapses after developing tolerance, the risk of generalized pustular psoriasis, and the development of local or systemic toxicity due to weakened skin barrier function. In the case of using the preparation for psoriasis, it is very important to closely monitor the patients.
    With a sudden cessation of long-term treatment, the effect of returning symptoms in the form of dermatitis with intense redness, irritation and burning may develop. This can be prevented by slowly discontinuing the preparation, such as intermittent treatment, until it is completely discontinued.
    GCS can change the signs of some lesions and complicate the diagnosis, which will also delay recovery.
    Elokom ointment and lotion contain propylene glycol, which can irritate the skin.
    Elokom is not intended for ophthalmic use, including application to the eyelids. Do not allow the preparation to come into contact with the eyes.
    With the use of systemic and local corticosteroids (including intranasal, inhalation and intraocular routes of administration), visual impairment may occur. If symptoms such as blurred vision or other visual impairments occur, the patient should be examined by an ophthalmologist to assess possible causes of visual impairment, which may include cataracts, glaucoma, or rare conditions such as central serous chorioretinopathy, as reported after systemic and local action.
    During pregnancy and breastfeeding. During pregnancy and lactation, treatment with the preparation  should be carried out only as directed by a doctor. However, in this case, it is necessary to avoid using the preparation on large areas of the skin or for a long period. There is no sufficient evidence of the safety of the preparation for women during pregnancy. As with other topical corticosteroids, Elokom should be prescribed to pregnant women only if the potential benefit to the mother outweighs the potential risk to the fetus.
    It is not known whether topical application of corticosteroids can cause significant systemic absorption, resulting in the amount of the preparation that can be detected in breast milk. Elokom should be used during breastfeeding only after careful analysis of the benefit / risk ratio. If you prescribe high doses of treatment or use the preparation for a long period, breastfeeding should be discontinued.
    Children. For children over 2 years of age, use the preparation only as directed by a doctor.
    Since the ratio of surface area to body weight in children is greater than in adults, children are at greater risk of suppression of the function of the hypothalamic-pituitary-adrenal system and manifestations of Cushing's syndrome when using any topical GCS, which increases when applied to an area of ​​more than 20% of the body surface.
    It is recommended to use the smallest amount of GCS necessary to obtain a therapeutic effect, especially in children. The course of treatment should not exceed 5 days. Long-term treatment with GCS can delay the growth and development of the child.
    The safety of using Elokom in children for more than 6 weeks has not been studied.
    There are only limited data on the treatment of children under 2 years of age.
    Mometasone should not be used to treat diaper dermatitis.
    Ointment / cream / lotion should not be applied under occlusive dressings unless directed by a doctor, and should not be applied to areas under diapers or panties that are impervious to moisture.
    The ability to influence the reaction rate when driving or working with other mechanisms. Not installed.

    Interactions

    Unknown.

    Overdose

    Excessive and prolonged use of local corticosteroids can cause inhibition of the function of the pituitary-adrenal system, which can cause the development of secondary adrenal cortex insufficiency, which is usually reversible.
    In case of inhibition of this system, the interval between applications should be increased, or corticosteroids with less activity should be used or the preparation should be canceled.
    The steroid content in each container is so small that in the unlikely event of accidental ingestion of the preparation, the toxic effect will be almost invisible or absent.

    Storage conditions

    Keep out of the reach of children at a temperature not exceeding 25 ° C.

    There are no reviews for this product.
    VEV Healthcare Store © 2017